Nivolumab

Min.Order / FOB Price:Get Latest Price

1 Milligram	Negotiable

1 Milligram

Negotiable

Min.Order :1 Milligram
Purity: 98.56%
Payment Terms : T/T

Keywords

BMS-936558 ONO-4538 MDX-1106

Quick Details

Appearance:Colorless to light yellow (Solution)
Application:Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
PackAge:1mg, 5mg
ProductionCapacity:|Metric Ton|Day
Storage:
Transportation:By Air

Superiority:

Product Name: Nivolumab

Appearance: Colorless to light yellow (Solution)

Purity (SEC-HPLC): 98.56%

Concentration: 10.0 mg/ml

Endotoxin Level: <0.5 EU/mg

Sterility: Sterilized via a 0.22 μm filter and packaged aseptically

Storage Buffer: PBS, pH 7.2

Details:

Biological Activity:

In Vitro: Nivolumab binds to CHO cells expressing PD-1 with an EC₅₀ of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC₅₀ of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC₅₀ values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus.

In Vivo: Nivolumab (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted.

View All